Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial-Reference-Cited by-同舟云学术

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Published:2009-02 Issue:9662 Volume:373 Page:473-481
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Garber Alan,Henry Robert,Ratner Robert,Garcia-Hernandez Pedro A,Rodriguez-Pattzi Hiromi,Olvera-Alvarez Israel,Hale Paula M,Zdravkovic Milan,Bode Bruce

Publisher

Elsevier BV

Subject

General Medicine

Reference17 articles.

1. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy;Kahn;N Engl J Med,2006

2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33);Lancet,1998

3. The physiology of glucagon-like peptide 1;Holst;Physiol Rev,2007

4. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration;Knudsen;J Med Chem,2000

5. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men;Agerso;Diabetologia,2002

Cited by 879 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes;The Lancet Diabetes & Endocrinology;2024-09

2. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review;Cureus;2024-09-01

3. Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management;Expert Review of Endocrinology & Metabolism;2024-08-28

4. Second Generation Anti-Obesity Medications;Current Pediatrics Reports;2024-08-20

5. GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management;Nature Metabolism;2024-08-19